Welcome to LookChem.com Sign In|Join Free
  • or

Encyclopedia

Vasotocin

Base Information Edit
  • Chemical Name:Vasotocin
  • CAS No.:9034-50-8
  • Molecular Formula:Unspecified
  • Molecular Weight:1050.22
  • Hs Code.:3504009000
  • Wikipedia:Vasotocin
  • Mol file:9034-50-8.mol
Vasotocin

Synonyms:(8-Arginine)Oxytocin;3 Isoleucyl Vasopressin;3-Isoleucyl Vasopressin;Arginine Oxytocin;Arginine Vasotocin;Argiprestocin;Argiprestocine;Isoleucyl Vasopressin;Non-Mammalian Vasopressin;Oxytocin, Arginine;Vasopressin, 3-Isoleucyl;Vasopressin, Isoleucyl;Vasopressin, Non Mammalian;Vasopressin, Non-Mammalian;Vasotocin;Vasotocin, Arginine

Suppliers and Price of Vasotocin
Supply Marketing:Edit
Business phase:
The product has achieved commercial mass production*data from LookChem market partment
Manufacturers and distributors:
  • Manufacture/Brand
  • Chemicals and raw materials
  • Packaging
  • price
  • Usbiological
  • Vasopressin
  • 100ug
  • $ 347.00
  • Apolloscientific
  • Vasopressin
  • 100mg
  • $ 553.00
  • Apolloscientific
  • Vasopressin
  • 25mg
  • $ 183.00
  • Apolloscientific
  • Vasopressin
  • 5mg
  • $ 75.00
Total 54 raw suppliers
Chemical Property of Vasotocin Edit
Chemical Property:
  • PSA:0.00000 
  • LogP:0.00000 
  • XLogP3:-5.1
  • Hydrogen Bond Donor Count:14
  • Hydrogen Bond Acceptor Count:16
  • Rotatable Bond Count:19
  • Exact Mass:1049.45350498
  • Heavy Atom Count:72
  • Complexity:1990
Purity/Quality:

99% *data from raw suppliers

Vasopressin *data from reagent suppliers

Safty Information:
  • Pictogram(s):  
  • Hazard Codes: 
MSDS Files:
Useful:
  • Canonical SMILES:CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
  • Recent EU Clinical Trials:Arginin Vasopressin im fortgeschrittenen vasodilatorischen Schock: Ein Dosisvergleich 2 vs. 4 IU/h
  • Biological functions The most prominent function of AVP is the antidiuretic action through V2aR/aquaporin-2 (AQP2) in the inner medullary collecting duct of the kidney. AVP administration also induces a large increase in blood pressure. This effect is caused by vascular contraction, basoreflex, renin production, and aldosterone and glucocorticoid releases from the adrenal gland, all of which are mediated via V1aR. In addition, adrenocorticotropic hormone (ACTH) and catecholamine release via V1bR and body fluid retention via V2aR contribute to blood pressure regulation. In the pituitary, AVP synergistically controls the secretion of ACTH with corticotropin-releasing hormone (CRH). AVP also regulates metabolic function via V1aR and V1bR. In the central nervous system, AVP is involved in social behaviors, learning, memory, aggression, anxiety, depression, water and food intake, circadian rhythm, and thermoregulation.
  • Description Vasopressin, also called antidiuretic hormone (A D H) or arginine vasopressin (AVP), is another hormone key to water homeostasis and blood pressure regulation. A rginine vasopressin is produced in the neurones of the hypothalamus and stored in vesicles within the posterior pituitary. Vasopressin is released in response to increased blood osmolality detected by hypothalamic osmoreceptors; systemic hypotension or hypovolaemia detected by cardiopulmonary baroreceptors of the great veins and atria; or angiotensin I I acting on the hypothalamus.
  • Uses Vasopressin is a peptide hormone secreted by the hypothalamus via the posterior pituitary. Its primary role is the regulation of body fluid balance. It is secreted in response to hypotension and promotes retention of water by action on specific cAMP-coupled V2 receptors. It causes vasoconstriction by stimulating V1 receptors in VSM and is particularly potent in hypotensive patients. It is increasingly used in the treatment of refractory vasodilatory shock which is resistant to catecholamines. The vasopressin analogue desmopressin is used to treat diabetes insipidus and in the management of von Willebrand's disease. Terlipressin (another analogue) is used to limit bleeding from oesophageal varices in patients with portal hypertension. When used for the management of low SVR states, vasopressin is administered as an i.v. infusion at a rate of 0.01–0.1 units min–1.
  • Biological Functions Human vasopressin, or Arg-vasopressin, is chemically very similar to oxytocin and therefore sometimes is referred to as [Phe3, Arg8]oxytocin. The physiological role of vasopressin is the regulation of water reabsorption in the renal tubules (an antidiuretic action, thus often referred to as the antidiuretic hormone). In high doses, vasopressin promotes the contraction of arterioles and capillaries, resulting in an increase in blood pressure, thus the name vasopressin. An inadequate output of pituitary antidiuretic hormone can cause diabetes insipidus, which is characterized by the chronic excretion of large amounts of pale urine and results in dehydration and extreme thirst.
  • Clinical Use The nonapeptide vasopressin is well known for its role on fluid metabolism, but it also is a key regulator of the HPA axis. Stress stimulates the release of vasopressin in the pituitary gland, where it strongly potentiates the effects of CRF on adrenocorticotropic hormone release. These findings suggest that HPA axis dysregulation in depression might be associated with the development of centrally acting vasopressin receptor antagonists for the treatment of depression. lly as a long-lasting and selective V2aR agonist for the treatment of central diabetes insipidus. For X-CNDI, the use of nonpeptide antagonists (pharmacological chaperones) and nonpeptide agonists (vaptans) has been tested. These cell-permeable reagents stabilize ERretained misfolded V2aR mutants, allowing the receptors to reach the plasma membrane or to initiate a cAMP response, leading to AQP2 translocation. Strategies bypassing nonfunctional or mislocalized V2aR to induce AQP2 translocation and phosphorylation have also been tested. OPC41061 (V2aR antagonist, tolvaptan) has been approved in the United States and Europe for the treatment of hyponatraemia in SIADH. Recently, the VP system (V1aR) was proposed as a novel therapeutic target for castration-resistant prostate cancer. The results of clinical trials to improve autism spectrum disorder by targeting the AVP/V1aR pathway have been reported.
Post RFQ for Price